EFTA02430496.pdf

To: jeevacation©gmaitcom[[email protected]] From: michael kates Sent Thur 1/28/2010 3:20:07 PM Subject: Acorda Therapeutics Jeffrey: I heard about the FDA approval of their drug earlier in the month. Their stock had a nice rise after the announcement, although now hovering at 27.35. This is great news for many with walking problems. Interesting enough, I know my physicians are to keeping me on a plateau awaiting this type of new MS therapy medication. As Faith may have mentioned, I'm exploring venues to help myself and others. In this connection, I thank you for all the information you have provided me. Best-Michael Michael H. Kates Note: This message contains information some or all of which, may be proprietary or legally privileged. It is for the intended recipient only. If you have received this message by error, please notify the sender and or company immediately and destroy the related message. You, the recipient, are obligated to maintain it in a safe, secure, and confidential manner. Unauthorized re-disclosure or failure could subject you to penalties described in federal and state law. EFTA_R1_01500459 EFTA02430496